Baudax Bio Inc (NASDAQ:BXRX) Stock Falls 11% In a Week: Here is Why

January 20, 2022

Pharmaceutical firm Baudax Bio Inc (NASDAQ:BXRX) has not had a great time in the markets in the past week and due to a steady selloff from investors, it has tanked by as much as 11%. Such a decline can also prove to be an opportunity in certain cases and hence, it may be a sound move to take a closer look into it. Trading Data On Wednesday, BXRX stock fell…

Read More >>

Baudax Bio Inc (NASDAQ:BXRX) Stock In Focus After Quarterly Earnings

November 5, 2021

The pharmaceutical company Baudax Bio Inc (NASDAQ:BXRX) was in focus yesterday after it announced its financial results for the quarter and the nine month period, both of which ended on September 30, 2021. Trading Data On Thursday, BXRX stock slid 6.22% at $0.5289 with more than 2.02 million shares, compared to its average volume of 3.17 million shares. The stock has moved within a range of $0.5300 – 0.5450 after…

Read More >>

Baudax Bio Inc (NASDAQ:BXRX) Stock Resumes Another Round Of Rally

September 2, 2021

The pharmaceutical company Baudax Bio Inc (NASDAQ:BXRX) has come on to the radars of many investors this week and on Wednesday, the stock was on the move as it ended the day with gains of as much as 13%. While the rally in the stock is substantial, it is also necessary to note that there has been no news about Baudax for some weeks and the last news to have…

Read More >>

Baudax Bio (NASDAQ:BXRX) Stock Sees Profit Taking At Higher Level

August 30, 2021

The Baudax Bio (NASDAQ:BXRX) stock was one of the notable movers last week and ahead of the start of another trading week, it could be a good time for investors to take a look at the stock. The stock had made a strong move last week but on Friday it fell sharply and went down by 10% as investors decided to book some of their profits. However, it should be…

Read More >>

Baudax Bio Inc. (NASDAQ:BXRX) Stock Rockets After The Big News: What Next?

August 25, 2021

Baudax Bio Inc. (NASDAQ:BXRX)soared 23% after announcing the filing of Form 4 SEC showing that its CFO Richard Casten has purchased a considerable number of its shares. Casten purchased around 50,000 shares at $0.51 per share.The company also announced its Q2 2021 financial results with total ANJESO vials sold during the quarter to end-users matching total vials sold the whole year last year. CEO Gerri Henwood said they are delighted…

Read More >>

Baudax Bio Inc (NASDAQ:BXRX) Stock is All Set To Gap-Up: How to Trade Now?

August 24, 2021

The pharmaceutical company Baudax Bio Inc (NASDAQ:BXRX) has had a pretty tough time in the markets over the course of the past month and that has been reflected in the price action in its stock, which has recorded a decline of 14% during the period. There has been no fresh news about the company in recent day but it might be a good time to take a look at the…

Read More >>